These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30879472)

  • 21. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
    Li A; Sun H; Du L; Wu X; Cao J; You Q; Li Y
    J Mol Model; 2014 Nov; 20(11):2515. PubMed ID: 25394401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond cysteine: recent developments in the area of targeted covalent inhibition.
    Mukherjee H; Grimster NP
    Curr Opin Chem Biol; 2018 Jun; 44():30-38. PubMed ID: 29857316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New drug design with covalent modifiers.
    Adeniyi AA; Muthusamy R; Soliman ME
    Expert Opin Drug Discov; 2016; 11(1):79-90. PubMed ID: 26757171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein structure and computational drug discovery.
    Nero TL; Parker MW; Morton CJ
    Biochem Soc Trans; 2018 Oct; 46(5):1367-1379. PubMed ID: 30242117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The existence of a second allosteric site on the M1 muscarinic acetylcholine receptor and its implications for drug design.
    Espinoza-Fonseca LM; Trujillo-Ferrara JG
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1217-20. PubMed ID: 16364641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Privileged structures as leads in medicinal chemistry.
    Costantino L; Barlocco D
    Curr Med Chem; 2006; 13(1):65-85. PubMed ID: 16457640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of (19)F-NMR in Fragment-Based Drug Discovery.
    Norton RS; Leung EW; Chandrashekaran IR; MacRaild CA
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
    Aljoundi A; Bjij I; El Rashedy A; Soliman MES
    Protein J; 2020 Apr; 39(2):97-105. PubMed ID: 32072438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Covalent Ligands via Noncovalent Docking by Dissecting Covalent Docking Based on a "Steric-Clashes Alleviating Receptor (SCAR)" Strategy.
    Ai Y; Yu L; Tan X; Chai X; Liu S
    J Chem Inf Model; 2016 Aug; 56(8):1563-75. PubMed ID: 27411028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico structure-based approaches to discover protein-protein interaction-targeting drugs.
    Shin WH; Christoffer CW; Kihara D
    Methods; 2017 Dec; 131():22-32. PubMed ID: 28802714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates: Design, synthesis and biological evaluation as potential anticancer agents.
    Kamal A; Vijaya Bharathi E; Janaki Ramaiah M; Dastagiri D; Surendranadha Reddy J; Viswanath A; Sultana F; Pushpavalli SN; Pal-Bhadra M; Srivastava HK; Narahari Sastry G; Juvekar A; Sen S; Zingde S
    Bioorg Med Chem; 2010 Jan; 18(2):526-42. PubMed ID: 20031423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.
    Li B; Zhao W; Zhang X; Wang J; Luo X; Baker SD; Jordan CT; Dong Y
    Bioorg Med Chem; 2016 Nov; 24(22):5855-5860. PubMed ID: 27687970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic Docking: A Paradigm Shift in Computational Drug Discovery.
    Gioia D; Bertazzo M; Recanatini M; Masetti M; Cavalli A
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29165360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMR structural studies on the covalent DNA binding of a pyrrolobenzodiazepine-naphthalimide conjugate.
    Rettig M; Langel W; Kamal A; Weisz K
    Org Biomol Chem; 2010 Jul; 8(14):3179-87. PubMed ID: 20490406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mimicking trimeric interactions in the aromatic side chains of the proteins: a gas phase study of indole...(pyrrole)2 heterotrimer.
    Kumar S; Das A
    J Chem Phys; 2012 May; 136(17):174302. PubMed ID: 22583225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and application of novel electrophilic warheads in target identification and drug discovery.
    Liu Y; Lv S; Peng L; Xie C; Gao L; Sun H; Lin L; Ding K; Li Z
    Biochem Pharmacol; 2021 Aug; 190():114636. PubMed ID: 34062128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
    Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
    J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of molecular dynamics simulations to evaluate the DNA sequence-selectivity of G-A cross-linking PBD-duocarmycin dimers.
    Jackson PJM; Rahman KM; Thurston DE
    Bioorg Med Chem Lett; 2017 Jan; 27(1):102-108. PubMed ID: 27889454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.